<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180880</url>
  </required_header>
  <id_info>
    <org_study_id>NeuropathicPain</org_study_id>
    <nct_id>NCT02180880</nct_id>
  </id_info>
  <brief_title>Symptom Based Treatment of Neuropathic Pain</brief_title>
  <official_title>Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ju Seok Ryu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Neuropathic pain in spinal cord injured patients

        1. Inclusion criteria

             -  pain intensity, visual analogue scale &gt; 3

             -  a LANSS (Leeds assessment of neuropathic symptoms and signs) score of 12 and above

             -  aged â‰¥20

        2. Method

             -  Stop pain medications

             -  Test oxcarbazepine (150mg twice daily) and pregabalin (150mg twice daily)

             -  Check pain intensity (VAS score) with Baron's classification
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study, pharmacologic treatment included pregabalin and oxcarbazepine.

      Stop medications such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), tramadol and
      anti-spastic drugs (baclofen, tizanidine) and other medications known to have effect on pain
      and the central nervous system prior to the study for at least 3 days.

        1. Pain intensity (VAS score)

             1. 4 spontaneous characters

                  -  electric

                  -  burning

                  -  pricking

                  -  numbness

             2. evoked pain

                  -  allodynia

                  -  heat hyperalgesia

                  -  pressure hyperalgesia

        2. Location of neuropathic pain

             1. neuropathic pain at level of spinal cord injury

             2. neuropathic pain below level of spinal cord injury

      2. Side effects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom based treatment of neuropathic pain</measure>
    <time_frame>2 week later</time_frame>
    <description>Pain intensity using Visual analogue scale (0~100)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Neuralgia</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Pregabalin and Oxcarbazpepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin and Oxcarbazepine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin and Oxcarbazepine</intervention_name>
    <description>Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.
Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.</description>
    <arm_group_label>Pregabalin and Oxcarbazpepine</arm_group_label>
    <other_name>Lyrica and Oxcarb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged than 20 years

          -  Neuropathic pain symptoms : LANSS (Leeds assessment of neuropathic symptoms and signs)
             score of 12 and above

          -  Visual analogue scale score of 3 and above

        Exclusion Criteria:

          -  No pregnancy

          -  systemic disease

          -  psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ju Seok Ryu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyounggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CHA University</investigator_affiliation>
    <investigator_full_name>Ju Seok Ryu</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Neuralgia</keyword>
  <keyword>Spinal cord</keyword>
  <keyword>Oxcarbazepine</keyword>
  <keyword>Pregabalin</keyword>
  <keyword>Drug therapy</keyword>
  <keyword>Algorithms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

